Evaluation of the combined effects of doxorubicin and bortezomib on the human acute lymphoblastic leukemia cell line
Curr Issues Pharm Med Sci., Vol. 32, No. 2, 87-91
Agnieszka Korga1*
, Ewelina Humeniuk2, Grzegorz Adamczuk2, Magdalena Iwan1,
Marta Ostrowska2, Iwona Luszczewska-Sierakowska3 ,Jarosław Dudka2
1 Independent Medical Biology Unit, Medical University of Lublin, Poland
2 Chair and Department of Toxicology, Medical University of Lublin, Poland
10.2478/cipms-2019-0017
© 2019 Author(s). This is an open access article distributed under the Creative Commons Attribution-NonComercial-No Derivs licence (http://creativecommons.org/licenses/by-nc-nd/3.0/)
Abstract
Increasing numbers of oncological patients and growing drug resistance ensure that new methods of cancer treatment are intensively sought. Combining drugs for a synergistic effect is one of several possible ways to mitigate this problem. This leads to reducing the effective drug dose and the occurrence of side effects. Doxorubicin (DOX) is an antineoplastic agent that has several mechanisms of action. DOX intercalates between base pairs of DNA helix, inhibits topoisomerase II and also forms reactive oxygen species. Bortezomib (BZT) is an antitumor agent belonging to the group of proteasome inhibitors. It has been observed that BZT triggers an oxidative stress response in vitro and in vivo.
Accumulation of oxidatively damaged proteins and the simultaneously blocking of the proteasome can be very damaging to the tumour cell. For this reason, the aim of the study was to assess the potentially synergistic effect of DOX and BZT on human acute lymphoblastic leukemia (ALL). In the work, the cells were treated with both agents and their combinations and the effect was evaluated on the basis of morphological assessment, MTT assay and level of reduced glutathione measurement.
The study has shown that on acute lymphoblastic leukemia cells, synergistic effects came about in the combination of 1nM BZT with a wide range of concentrations of DOX. Herein, the visible, coactive effect of DOX and BZT was observed on oxidative stress levels. This phenomenon can be essential in blunting the possibility of rapid manifestation of resistance seen in BZT monotherapy. In addition, the needed very low concentrations of DOX reduce the risk of therapy side effect.
Full Text
Keywords
doxorubicin, bortezomib, lymphoblastic leukemia, oxidative stress.
References
- Field-Smith A, Morgan GJ, Davies FE. Bortezomib (Velcade™) in the treatment of multiple myeloma, Ther and Clin Risk Manag. 2006; 2:271-9.
- Romaniuk W, Ołdziej AE, Zińczuk J, Kłoczko J. Proteasome inhibitors in cancer therapy. Postepy Hig Med Dosw. 2015;69: 1443-50.
- Carvalho C, Santos RX, Cardoso S, Correia S, Oliveira PJ, Santos MS, Moreira PI. Doxorubicin: the good, the bad and the ugly effect. Curr Med Chem. 2009;16:3267-85.
- Lipchick BC, Fink EE, Nikiforov MA. Oxidative stress and proteasome inhibitors in multiple myeloma. Pharmacol Res. 2016; 105:210-5.
- Perez-Galan P, Roue G, Villamor N, Montserrat E, Campo E, Colomer D. The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status. Blood. 2006;107:257-64.
- Ling YH, Liebes L, Zou Y, Perez-Soler R. Reactive Oxygen Species Generation and Mitochondrial Dysfunction in the Apoptotic Response to Bortezomib, a Novel Proteasome Inhibitor, in Human H460 Non-small Cell Lung Cancer Cells. J Biol Chem. 2003;278: 33714-23.
- Fribley A, Zeng Q, Wang CY. Proteasome inhibitor PS-341 induces apoptosis through induction of endoplasmic reticulum stress-reactive oxygen species in head and neck squamous cell carcinoma cells. Mol Cell Biol. 2004;24:9695-704.
- Ning YM, He K, Dagher R, Sridhara R, Farrell AT, Justice R et al. Liposomal doxorubicin in combination with bortezomib for relapsed or refractory multiple myeloma. Oncology. 2007;21:1503-8.
- Kumar SK, Callander NS, Alsina M, Atanackovic D, Biermann JS, Chandler JC et al. Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017;15:230-69.
- https://clinicaltrials.gov/ct2/results?cond=&term=bortezomib%2C+doxorubicin&cntry=&state=&city=&dist= open access: 01.09.2018
- Terwilliger T, Abdul-Hay M. Acute lymphoblastic leukemia: a comprehensive review and 2017 update. Blood Cancer Journal. 2017;7:e577.
- ClinicalTrials.gov Identifier: NCT00440726
- https://clinicaltrials.gov/ct2/show/NCT00440726?term=bortezomib%2C+doxorubicin&cond=ALL%2C+Childhood&rank=1 open access: 01.09.2018
- Shah JJ, Orlowski RZ, Thomas SK. Role of combination bortezomib and pegylated liposomal doxorubicin in the management of relapsed and/or refractory multiple myeloma. Ther and Clin Risk Manag. 2009;5:151-9.
- Horton TM, Gannavarapu A, Blaney SM, D’Argenio DZ, Plon SE, Berg SL. Bortezomib interactions with chemotherapy agents in acute leukemia in vitro. Cancer Chemother Pharmacol. 2006;58:13-23.
- Irimia R, Tofolean IT, Sandu RG, Băran OE, Ceauşescu MC, Coşoreanu V et al. Quercetin, Menadione, Doxorubicin combination as a potential alternative to Doxorubicin monotherapy of acute lymphoblastic leukemia. Documenta Haematologica. 2015;24.
